RPRX vs TXN · P/E 15, rev $1.30B vs P/E 52, rev $10.29B
Royalty Pharma Plc (RPRX) versus Texas Instruments Incorporated (TXN) — a side-by-side from cached financials, not a winner call.
Royalty Pharma Plc (RPRX) is a biotechnology company listed on US.
Texas Instruments Incorporated (TXN) is a semiconductors company listed on NASDAQ.
Latest reported RPRX revenue for 2026-06-30 was $1.30B. Net income was $312.6M. RPRX currently screens at market cap $20.45B and trailing P/E 14.8.
Latest reported TXN revenue for 2026-06-30 was $10.29B. Net income was $3.52B. TXN currently screens at market cap $274.74B and trailing P/E 51.7.
RPRX currently screens at market cap $20.45B and trailing P/E 14.8. TXN currently screens at market cap $274.74B and trailing P/E 51.7.
Not investment advice. Open the RPRX and TXN stock pages for the full models.
Not investment advice.